裴氏升血颗粒联合伊马替尼治疗慢性粒细胞白血病临床研究

Clinical Study of Peishi Shengxue Granule Combined with Imatinib for Chronic Myeloid Leukemia

目的:观察裴氏升血颗粒联合伊马替尼治疗慢性粒细胞白血病的临床疗效。方法:选取60例慢性粒细胞白血病患者,随机分为2组各30例,治疗组服用裴氏升血颗粒联合伊马替尼治疗,对照组只服用伊马替尼治疗,2组均治疗3月。观察2组患者临床表现、外周血象、骨髓象、免疫功能的变化以及不良反应的发生情况。结果:治疗3月后,治疗组缓解率(93.33%)高于对照组(76.67%),差异有统计学意义(P<0.05)。2组CD3+、CD4+及CD4+/CD8+比值均较治疗前升高(P<0.05),而治疗组CD3+、CD4+及CD4+/CD8+比值均高于对照组,差异均有统计学意义(P<0.05)。治疗组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:裴氏升血颗粒联合伊马替尼治疗的效果优于单纯伊马替尼治疗,裴氏升血颗粒可以减轻伊马替尼的副反应,提高患者的生活质量。

Objective：To observe the clinical curative effect of Peishi Shengxue granule combined with imatinib for chronic myeloid leukemia.Methods：Selected 60 patients with chronic myeloid leukemia,and divided them into two groups randomly.The treatment group was treated with Peishi Shengxue granule combined with imatinib,while the control group was given imatinib only.The two group were treated for three months.Observed variation of clinical manifestation,peripheral hemogram,myelogram,immune function,and incidence of adverse reaction ofthe two groups.Results：Afterthree months of treatment,remission rate ofthe treatment group was 93.33%,being higher than the 76.67%ofthe control group（P〈0.05）.CD3^＋,CD4^＋and the ratio of CD4^＋/CD8^＋ in the 2 groups were allhigher than those before treatment（P〈0.05）,and CD3^＋,CD4^＋ and the ratio of CD4^＋/CD8^＋ in the treatment group after treatment were higher than those in the control group（P〈0.05）.Incidence rate of adverse reaction in the treatment group was higher than that in the control group（P〈0.05）.Conclusion：The combination usage of Peishi Shengxue granule and imatinib was better than use imatinib only,for Peishi Shengxue granule can relieve adverse reaction which caused by imatinib,and improve quality of life in patients.